Oncimmune® is an industry leader in early cancer detection. The company is committed to advancing early cancer detection through proprietary autoantibody assay technologies based on biological technology identified by John Robertson, M.D., Professor of Surgery at Nottingham University. The company’s mission is to develop early cancer detection tests to identify more than 90 percent of solid-tumour cancers, which make up 70 percent of all cancers including lung, breast, colorectal, prostate, stomach, pancreatic and ovarian.
If you are a member of the media and would like more information about Oncimmune.
General Press Enquiries:
Phone: +44 (0)115 8231869
Fax: +44 (0)115 8231958